EP2348023B9
(en)
|
2005-12-13 |
2017-03-08 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
US7989459B2
(en)
|
2006-02-17 |
2011-08-02 |
Pharmacopeia, Llc |
Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
|
CL2007002866A1
(es)
|
2006-10-04 |
2008-07-04 |
Pharmacopeia Inc |
Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
|
US7902187B2
(en)
|
2006-10-04 |
2011-03-08 |
Wyeth Llc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
AR063141A1
(es)
|
2006-10-04 |
2008-12-30 |
Pharmacopeia Inc |
Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
|
CN101932582B
(zh)
|
2007-06-13 |
2013-09-25 |
因塞特公司 |
詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐
|
EA201000341A1
(ru)
*
|
2007-08-23 |
2010-10-29 |
Астразенека Аб |
2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений
|
WO2009085185A1
(en)
*
|
2007-12-19 |
2009-07-09 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
UY31631A1
(es)
|
2008-02-06 |
2009-09-30 |
|
Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
|
EP2255830A1
(en)
*
|
2008-03-03 |
2010-12-01 |
Takeda Pharmaceutical Company Limited |
Concomitant drug
|
WO2009126584A1
(en)
|
2008-04-07 |
2009-10-15 |
Amgen Inc. |
Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
|
TW201002713A
(en)
*
|
2008-04-09 |
2010-01-16 |
Organon Nv |
Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as PKC-theta inhibitors
|
EP2291187B1
(en)
|
2008-04-24 |
2018-08-15 |
Newlink Genetics Corporation |
Ido inhibitors
|
WO2009152027A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Merck & Co., Inc. |
5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition
|
DK2331547T3
(da)
*
|
2008-08-22 |
2014-11-03 |
Novartis Ag |
Pyrrolopyrimidinforbindelser som CDK-inhibitorer
|
WO2010045451A1
(en)
*
|
2008-10-16 |
2010-04-22 |
Glaxosmithkline Llc |
Pyrrolopyrimidine compounds
|
GB0903759D0
(en)
|
2009-03-04 |
2009-04-15 |
Medical Res Council |
Compound
|
CA2761896A1
(en)
|
2009-05-13 |
2010-11-18 |
The University Of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
CN102458581B
(zh)
|
2009-05-22 |
2016-03-30 |
因塞特控股公司 |
作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2,3-d]嘧啶和吡咯-3-基-吡咯并[2,3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物
|
SG176111A1
(en)
|
2009-05-22 |
2011-12-29 |
Incyte Corp |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
US9249145B2
(en)
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
DK2493895T3
(en)
|
2009-10-29 |
2017-08-14 |
Vectura Ltd |
N-CONTRIBUTING HETEROYEER DERIVATIVES AS JAK3 KINase INHIBITORS
|
US20130022629A1
(en)
*
|
2010-01-04 |
2013-01-24 |
Sharpe Arlene H |
Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
|
DK2536706T3
(en)
|
2010-02-11 |
2017-08-14 |
Celgene Corp |
ARYLMETHOXYISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPREHENSIVE AND PROCEDURES FOR USING SAME
|
UY33226A
(es)
*
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
ME02386B
(me)
|
2010-03-10 |
2016-09-20 |
Incyte Holdings Corp |
Derivati piperidin-4-il azetidina kao inhibitori jak1
|
ES2689177T3
(es)
*
|
2010-04-13 |
2018-11-08 |
Novartis Ag |
Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
WO2011146313A1
(en)
|
2010-05-19 |
2011-11-24 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
KR102303885B1
(ko)
|
2010-05-21 |
2021-09-24 |
인사이트 홀딩스 코포레이션 |
Jak 저해제에 대한 국소 제형
|
EP2955183A1
(en)
*
|
2010-10-25 |
2015-12-16 |
G1 Therapeutics, Inc. |
Cdk inhibitors
|
US20120115878A1
(en)
*
|
2010-11-10 |
2012-05-10 |
John Vincent Calienni |
Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
|
WO2012068381A2
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
EP2640723A1
(en)
|
2010-11-19 |
2013-09-25 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
CN103476776B
(zh)
*
|
2011-01-07 |
2016-09-28 |
北京赛林泰医药技术有限公司 |
作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
|
CN102093364B
(zh)
*
|
2011-01-07 |
2015-01-28 |
北京赛林泰医药技术有限公司 |
作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
|
AU2012216893B2
(en)
|
2011-02-17 |
2016-08-11 |
Cancer Therapeutics Crc Pty Limited |
FAK inhibitors
|
AU2012216894B2
(en)
|
2011-02-17 |
2016-07-14 |
Cancer Therapeutics Crc Pty Limited |
Selective FAK inhibitors
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
JP6277121B2
(ja)
|
2011-03-22 |
2018-02-07 |
アドヴィナス・セラピューティックス・リミテッド |
置換された縮合三環式化合物、その組成物および医学的応用
|
MY161199A
(en)
|
2011-03-23 |
2017-04-14 |
Amgen Inc |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
CA2836417A1
(en)
*
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Azaindole derivatives as tyrosine kinase inhibitors
|
US8691807B2
(en)
|
2011-06-20 |
2014-04-08 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
|
RU2014103250A
(ru)
*
|
2011-07-01 |
2015-08-10 |
Новартис Аг |
Комбинированная терапия
|
ES2676180T3
(es)
|
2011-07-01 |
2018-07-17 |
Novartis Ag |
Terapia de combinación que comprende un inhibidor de CDK4/6 y un inhibidor de PI3K para el uso en el tratamiento de cáncer
|
ES2548414T3
(es)
|
2011-07-08 |
2015-10-16 |
Novartis Ag |
Novedosos derivados de pirrolo pirimidina
|
WO2013017479A1
(en)
*
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
WO2013017480A1
(en)
*
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
BR112014007788A2
(pt)
|
2011-10-03 |
2017-04-18 |
Univ North Carolina Chapel Hill |
compostos de pirrolopirimidina para tratamento do câncer
|
WO2013059634A1
(en)
|
2011-10-20 |
2013-04-25 |
The Regents Of The University Of California |
Use of cdk9 inhibitors to reduce cartilage degradation
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
CN104302627A
(zh)
|
2012-05-22 |
2015-01-21 |
北卡罗来纳大学教堂山分校 |
用于治疗癌症的嘧啶化合物
|
EP2861231B1
(en)
*
|
2012-06-14 |
2016-08-31 |
Eli Lilly and Company |
Inhibitor of jak1 and jak2
|
CA2880764C
(en)
|
2012-08-03 |
2022-08-30 |
Foundation Medicine, Inc. |
Human papilloma virus as predictor of cancer prognosis
|
GB201216018D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Pharmacologically active compounds
|
GB201216017D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
WO2014045305A1
(en)
|
2012-09-21 |
2014-03-27 |
Advinus Therapeutics Limited |
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
|
CA2885259A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
|
WO2014062774A1
(en)
|
2012-10-17 |
2014-04-24 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
EA201590930A1
(ru)
|
2012-11-15 |
2015-08-31 |
Инсайт Корпорейшн |
Лекарственные формы руксолитиниба с замедленным высвобождением
|
EP2925752A4
(en)
|
2012-11-27 |
2016-06-01 |
Univ North Carolina |
PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
|
EP2742940B1
(en)
|
2012-12-13 |
2017-07-26 |
IP Gesellschaft für Management mbH |
Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
|
ES2676177T3
(es)
*
|
2012-12-20 |
2018-07-17 |
Novartis Ag |
Una combinación farmacéutica que comprende binimetinib
|
WO2014130693A1
(en)
*
|
2013-02-25 |
2014-08-28 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
EP3327144B1
(en)
|
2013-02-25 |
2020-03-25 |
Novartis AG |
Novel androgen receptor mutation
|
AU2014224976B2
(en)
*
|
2013-03-05 |
2017-09-28 |
Merck Patent Gmbh |
9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
|
JP6397831B2
(ja)
|
2013-03-06 |
2018-09-26 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Jak阻害剤の製造方法及びその中間体
|
MX2015013466A
(es)
|
2013-03-21 |
2016-06-21 |
Novartis Ag |
Terapia de combinacion que comprende un inhibidor deb-raf y un segundo inhibidor.
|
EP2986740B1
(en)
|
2013-04-16 |
2020-01-15 |
Memorial Sloan-Kettering Cancer Center |
Companion diagnostic for cdk4 inhibitors
|
HUE031980T2
(en)
|
2013-04-25 |
2017-08-28 |
Beigene Ltd |
Condensed heterocyclic compounds as protein kinase inhibitors
|
US8895611B1
(en)
|
2013-07-17 |
2014-11-25 |
King Fahd University Of Petroleum And Minerals |
Cytotoxic compounds for treating cancer
|
MY195091A
(en)
|
2013-08-07 |
2023-01-10 |
Incyte Corp |
Sustained Release Dosage Forms for a JAK1 Inhibitor
|
CN103408546A
(zh)
*
|
2013-08-22 |
2013-11-27 |
中国药科大学 |
2-苯氨基嘌呤类plk1抑制剂及其用途
|
HUE049281T2
(hu)
|
2013-09-13 |
2020-09-28 |
Beigene Switzerland Gmbh |
Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
AU2015238305B2
(en)
|
2014-03-26 |
2020-06-18 |
Astex Therapeutics Ltd |
Combinations of an FGFR inhibitor and an IGF1R inhibitor
|
EP3122358B1
(en)
|
2014-03-26 |
2020-12-16 |
Astex Therapeutics Ltd. |
Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
|
WO2015157125A1
(en)
|
2014-04-11 |
2015-10-15 |
The University Of North Carolina At Chapel Hill |
Therapuetic uses of selected pyrazolopyrimidine compounds with anti-mer tyrosine kinase activity
|
US20150320754A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
CA2950330C
(en)
*
|
2014-05-28 |
2019-04-30 |
Shanghai Fochon Pharmaceutical Co Ltd |
Certain protein kinase inhibitors
|
ES2873959T3
(es)
|
2014-05-28 |
2021-11-04 |
Piramal Entpr Ltd |
Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
WO2016000619A1
(en)
|
2014-07-03 |
2016-01-07 |
Beigene, Ltd. |
Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
|
AU2015292425B2
(en)
*
|
2014-07-24 |
2018-12-20 |
Beta Pharma, Inc. |
2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof
|
JP6884701B2
(ja)
|
2014-10-06 |
2021-06-09 |
シグナル ファーマシューティカルズ,エルエルシー |
置換アミノプリン化合物、その組成物、及びそれによる治療の方法
|
CA3000633C
(en)
|
2014-10-14 |
2023-10-03 |
The Regents Of The University Of California |
Use of cdk9 and brd4 inhibitors to inhibit inflammation
|
CN105111215B
(zh)
*
|
2014-12-12 |
2019-06-18 |
苏州晶云药物科技股份有限公司 |
一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
|
CN104610265A
(zh)
*
|
2014-12-31 |
2015-05-13 |
芜湖杨燕制药有限公司 |
一种化合物及其制备方法
|
CN104606197A
(zh)
*
|
2014-12-31 |
2015-05-13 |
芜湖杨燕制药有限公司 |
一种化合物的抗肿瘤用途
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
CN107801397B
(zh)
*
|
2015-02-13 |
2021-07-30 |
达纳-法伯癌症研究所公司 |
Lrrk2抑制剂及其制备和使用方法
|
CN106146515B
(zh)
*
|
2015-04-17 |
2020-09-04 |
常州隆赛医药科技有限公司 |
新型激酶抑制剂的制备及应用
|
SI3353177T1
(sl)
|
2015-09-23 |
2020-08-31 |
Janssen Pharmaceutica Nv |
Triciklični heterocikli za zdravljenje raka
|
HRP20220012T1
(hr)
|
2015-09-23 |
2022-04-01 |
Janssen Pharmaceutica Nv |
Bi-heteroaril supstituirani 1,4-benzodiazepini i njihova upotreba za liječenje raka
|
WO2017114351A1
(en)
*
|
2015-12-27 |
2017-07-06 |
Chongqing Fochon Pharmaceutical Co., Ltd. |
Certain protein kinase inhibitors
|
CN106928219B
(zh)
|
2015-12-31 |
2021-08-20 |
上海医药集团股份有限公司 |
含氮稠杂环化合物、制备方法、中间体、组合物和应用
|
WO2017156263A1
(en)
|
2016-03-09 |
2017-09-14 |
Memorial Sloan-Kettering Cancer Center |
Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
|
US10709708B2
(en)
|
2016-03-17 |
2020-07-14 |
The University Of North Carolina At Chapel Hill |
Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
|
DK3436019T3
(da)
|
2016-04-01 |
2021-10-11 |
Signal Pharm Llc |
(1s,4s)-4-(2-(((3s,4r)-3-fluortetrahydro-2h-pyran-4-yl)amino)-8-((2,4,6-trichlorphenyl)amino)-9h-purin-9-yl)-1-methylcyclohexan-1-carboxamid og fremgangsmåder til anvendelse deraf
|
CN109069512B
(zh)
|
2016-04-01 |
2022-06-14 |
西格诺药品有限公司 |
取代的氨基嘌呤化合物、其组合物以及相关治疗方法
|
EP3481393B1
(en)
|
2016-07-05 |
2021-04-14 |
Beigene, Ltd. |
Combination of a pd-1 antagonist and a raf inhibitor for treating cancer
|
TW202233628A
(zh)
|
2016-08-16 |
2022-09-01 |
英屬開曼群島商百濟神州有限公司 |
(s)-7-(1-丙烯醯基六氫吡啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑並[1,5-a]嘧啶-3-甲醯胺的晶型、其製備和用途
|
FI3500299T3
(fi)
|
2016-08-19 |
2024-02-14 |
Beigene Switzerland Gmbh |
Tsanubrutinibin yhdistelmä cd20-tai pd-1-vasta-aineen kanssa käytettäväksi syövän hoidossa
|
SG11201901472TA
(en)
|
2016-08-23 |
2019-03-28 |
Eisai R&D Man Co Ltd |
Combination therapies for the treatment of hepatocellular carcinoma
|
MA46285A
(fr)
|
2016-09-19 |
2019-07-31 |
Mei Pharma Inc |
Polythérapie
|
US10849903B2
(en)
|
2016-10-20 |
2020-12-01 |
Pfizer Inc. |
Anti-proliferative agents for treating PAH
|
WO2018081211A1
(en)
*
|
2016-10-26 |
2018-05-03 |
Li George Y |
Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
|
EP3541391A4
(en)
*
|
2016-11-17 |
2020-06-17 |
The University of North Carolina at Chapel Hill |
ALKYL-PYRROLOPYRIMIDINE ANALOG AND METHOD FOR THE PRODUCTION AND USE THEREOF
|
BR112019012217B1
(pt)
|
2016-12-20 |
2021-08-10 |
Astrazeneca Ab |
Compostos, formas cristalinas, composição farmacêutica e uso de um composto ou seu sal farmaceuticamente aceitável
|
EP3560926B1
(en)
*
|
2016-12-21 |
2022-02-23 |
Ono Pharmaceutical Co., Ltd. |
6-amino-7,9-dihydro-8h-purin-8-one compounds as brk inhibitors
|
JP7076741B2
(ja)
|
2016-12-27 |
2022-05-30 |
国立研究開発法人理化学研究所 |
Bmpシグナル阻害化合物
|
US11555038B2
(en)
|
2017-01-25 |
2023-01-17 |
Beigene, Ltd. |
Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
US11578067B2
(en)
|
2017-01-30 |
2023-02-14 |
Kyoto University |
Compound, and method for producing regulatory T cells
|
MX2019010981A
(es)
|
2017-03-16 |
2020-09-07 |
Eisai R&D Man Co Ltd |
Terapias de combinacion para el tratamiento de cancer de mama.
|
TW201904577A
(zh)
|
2017-06-16 |
2019-02-01 |
美商貝達醫藥公司 |
N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物
|
GB201709840D0
(en)
|
2017-06-20 |
2017-08-02 |
Inst Of Cancer Research: Royal Cancer Hospital |
Methods and medical uses
|
US11597768B2
(en)
|
2017-06-26 |
2023-03-07 |
Beigene, Ltd. |
Immunotherapy for hepatocellular carcinoma
|
WO2019034009A1
(en)
|
2017-08-12 |
2019-02-21 |
Beigene, Ltd. |
BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
|
CA3077238C
(en)
*
|
2017-09-28 |
2022-04-12 |
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. |
4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof
|
JP2020536100A
(ja)
|
2017-10-04 |
2020-12-10 |
セルジーン コーポレイション |
シス−4−[2−{[(3s,4r)−3−フルオロキサン−4−イル]アミノ}−8−(2,4,6−トリクロロアニリノ)−9h−プリン−9−イル]−1−メチルシクロヘキサン−1−カルボキサミドの製造プロセス
|
WO2019070845A1
(en)
|
2017-10-04 |
2019-04-11 |
Celgene Corporation |
COMPOSITIONS AND METHODS OF USING CIS-4- [2 - {[(3S, 4R) -3-FLUOROOXAN-4-YL] AMINO} -8- (2,4,6-TRICHLOROANILINO) -9H-PURINE-9 yl] -1-methylcyclohexane-1-carboxamide
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
JP7337395B2
(ja)
|
2018-01-29 |
2023-09-04 |
ベータ ファーマ,インコーポレイテッド |
Cdk4およびcdk6阻害剤としての2h-インダゾール誘導体およびその治療上の使用
|
CR20200379A
(es)
|
2018-01-30 |
2021-03-05 |
Incyte Corp |
Procesos e intermedio para elaborar un inhibidor de jak campo técnico
|
CA3095487A1
(en)
|
2018-03-30 |
2019-10-03 |
Incyte Corporation |
Treatment of hidradenitis suppurativa using jak inhibitors
|
WO2019195959A1
(en)
|
2018-04-08 |
2019-10-17 |
Cothera Biosciences, Inc. |
Combination therapy for cancers with braf mutation
|
US10723739B2
(en)
|
2018-05-14 |
2020-07-28 |
Apotex Inc. |
Processes for the preparation of Ribociclib and intermediates thereof
|
WO2019222524A1
(en)
*
|
2018-05-16 |
2019-11-21 |
The University Of North Carolina At Chapel Hill |
Alkyl pyrrolopyrimidines as pan-tam inhibitors and their application in cancer treatment
|
CN110577524B
(zh)
*
|
2018-06-07 |
2022-01-28 |
北京大学深圳研究生院 |
一种激酶选择性抑制剂
|
CN109438447B
(zh)
*
|
2018-09-11 |
2020-10-16 |
北京工业大学 |
5,7-二氢-6H-吡咯并[2,3-d]嘧啶-6-酮类衍生物制备方法和应用
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
US20220056037A1
(en)
*
|
2018-12-28 |
2022-02-24 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
US20230065740A1
(en)
*
|
2018-12-28 |
2023-03-02 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
CN114269734A
(zh)
|
2019-05-08 |
2022-04-01 |
维玛兰生物科学公司 |
Jak抑制剂
|
US11434291B2
(en)
|
2019-05-14 |
2022-09-06 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
TW202110849A
(zh)
*
|
2019-05-27 |
2021-03-16 |
大陸商迪哲(江蘇)醫藥股份有限公司 |
Dna依賴性蛋白激酶抑制劑
|
CN110305140B
(zh)
*
|
2019-07-30 |
2020-08-04 |
上海勋和医药科技有限公司 |
二氢吡咯并嘧啶类选择性jak2抑制剂
|
KR20220051351A
(ko)
*
|
2019-08-08 |
2022-04-26 |
비말란 바이오사이언스즈, 인크. |
Jak 억제제
|
JP2023509260A
(ja)
|
2019-08-14 |
2023-03-08 |
インサイト・コーポレイション |
Cdk2阻害剤としてのイミダゾリルピリミジニルアミン化合物
|
GB201911868D0
(en)
*
|
2019-08-19 |
2019-10-02 |
Galapagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
|
AU2020354629A1
(en)
*
|
2019-09-25 |
2022-04-21 |
Vimalan Biosciences, Inc. |
JAK inhibitors
|
WO2021072232A1
(en)
|
2019-10-11 |
2021-04-15 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
EP4046999A4
(en)
*
|
2019-10-17 |
2023-11-22 |
Cisen Pharmaceutical Co., Ltd. |
AMINOPYRIMIDINE COMPOUND USED AS TRIPLE INHIBITOR OF CDK2/4/6
|
US20230357248A1
(en)
*
|
2019-11-13 |
2023-11-09 |
Medshine Discovery Inc. |
Pyrrolopyrimidine compound as btk inhibitor and use thereof
|
CA3164617A1
(en)
*
|
2019-12-16 |
2021-06-24 |
Lunella Biotech, Inc. |
Selective cdk4/6 inhibitor cancer therapeutics
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
US11691971B2
(en)
|
2020-06-19 |
2023-07-04 |
Incyte Corporation |
Naphthyridinone compounds as JAK2 V617F inhibitors
|
US11753413B2
(en)
|
2020-06-19 |
2023-09-12 |
Incyte Corporation |
Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
|
KR102409595B1
(ko)
*
|
2020-06-29 |
2022-06-17 |
한국과학기술연구원 |
단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
|
EP4175719A1
(en)
|
2020-07-02 |
2023-05-10 |
Incyte Corporation |
Tricyclic urea compounds as jak2 v617f inhibitors
|
US11767323B2
(en)
|
2020-07-02 |
2023-09-26 |
Incyte Corporation |
Tricyclic pyridone compounds as JAK2 V617F inhibitors
|
WO2022046989A1
(en)
|
2020-08-27 |
2022-03-03 |
Incyte Corporation |
Tricyclic urea compounds as jak2 v617f inhibitors
|
CZ309356B6
(cs)
*
|
2020-09-15 |
2022-09-28 |
Ústav experimentální botaniky AV ČR, v. v. i |
Substituované purinové sloučeniny jako inhibitory proteinkináz, jejich použití jako léčiva a farmaceutické přípravky obsahující tyto deriváty
|
CN112375081B
(zh)
*
|
2020-11-23 |
2022-04-12 |
中国医学科学院医药生物技术研究所 |
具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
|
CN116685323A
(zh)
*
|
2020-12-21 |
2023-09-01 |
江苏恒瑞医药股份有限公司 |
嘌呤酮衍生物、其制备方法及其在医药上的应用
|
US11919908B2
(en)
|
2020-12-21 |
2024-03-05 |
Incyte Corporation |
Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
|
EP4298099A1
(en)
|
2021-02-25 |
2024-01-03 |
Incyte Corporation |
Spirocyclic lactams as jak2 v617f inhibitors
|
EP4313987A2
(en)
|
2021-04-01 |
2024-02-07 |
KRKA, d.d., Novo mesto |
Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof
|
WO2022226290A1
(en)
*
|
2021-04-22 |
2022-10-27 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
2-phenylamino pyrrolopyrimidines as ack1 inhibitors
|
AU2022306297A1
(en)
|
2021-07-09 |
2024-02-08 |
Plexium, Inc. |
Aryl compounds and pharmaceutical compositions that modulate ikzf2
|
US11786531B1
(en)
|
2022-06-08 |
2023-10-17 |
Beigene Switzerland Gmbh |
Methods of treating B-cell proliferative disorder
|
WO2023241620A1
(en)
*
|
2022-06-14 |
2023-12-21 |
Suzhou Keen Therapeutics Co., Ltd. |
Biologically active compounds and methods thereof
|
WO2024049926A1
(en)
|
2022-08-31 |
2024-03-07 |
Arvinas Operations, Inc. |
Dosage regimens of estrogen receptor degraders
|
CN117720532A
(zh)
*
|
2022-09-16 |
2024-03-19 |
华东师范大学 |
作为rsk抑制剂的吡咯并嘧啶衍生物及其应用
|